Key Drivers
- Strong liquidity
- Persistent losses
- Financing-dependent
AIAI Summary
IMNM's Phase 3 win transforms it from an R&D burn story into an event‑driven, near‑term commercial opportunity centered on varegacestat—reducing binary early‑stage risk but concentrating valuation on a single small‑population program whose regulatory, pricing and commercialization execution (and likely future equity raises) will determine upside versus substantial dilution downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Persistent losses
- •Financing-dependent
IMNM is cash-rich with very strong short-term liquidity and low leverage but remains unprofitable with heavy R&D burn, negligible revenue, negative free cash flow, and dependence on financing despite a premium market valuation. #cash-rich
Price Behavior
Key Price Behavior Insights:
- •Near support
- •Failed reclaim
- •Downward momentum
Price is trending down over the last month (≈−7%), trading near short-term support around $20.00 after peaking at $22.52 and failing to reclaim $22.5 resistance, signaling downside momentum unless buyers push a reversal with confirming volume.
Sharp peak at $22.52 on 2026-03-04 then decline toward range low
Sentiment & News
Key News Insights:
- •RINGSIDE efficacy
- •NDA planned
- •Major exit
Immunome reported strong Phase 3 RINGSIDE data supporting a planned Q2 2026 NDA for varegacestat and continued hiring, even as a major investor fully exited its position.
Positive trial data and a near-term regulatory pathway should re-rate the stock if commercial prospects withstand a small patient base and investor churn
Similar Companies in Healthcare
Other companies in the same sector with AI ratings